Certain chemical entities, compositions and methods
申请人:Morgan P. Bradley
公开号:US20070197507A1
公开(公告)日:2007-08-23
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Certain Chemical Entities, Compositions and Methods
申请人:Morgan Bradley P.
公开号:US20100210634A1
公开(公告)日:2010-08-19
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Certain chemical entities, compositions, and methods
申请人:Cytokinetics, Inc.
公开号:US08653081B2
公开(公告)日:2014-02-18
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
申请人:Cytokinetics, Inc.
公开号:US20130296335A1
公开(公告)日:2013-11-07
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
申请人:GLAXO GROUP LIMITED
公开号:US20150299121A1
公开(公告)日:2015-10-22
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.